BPC-157 vs GHK-Cu
Verdict: Different repair departments. BPC-157 is the tendon-ligament-gut compound: systemic or near-site injections during active injury rehab. GHK-Cu is the remodeling compound: collagen synthesis, wound cosmetics, skin quality and hair — used as much topically as injected. People comparing them usually have an injury (answer: BPC-157) or a skin/anti-aging goal (answer: GHK-Cu); the overlap is mostly in wound healing, where they attack different phases.
Side by side
| BPC-157 | GHK-Cu | |
|---|---|---|
| Typical dose | 250 mcg–500 mcg | 1 mg–2 mg |
| Frequency | 1–2x daily | daily |
| Administration | subcutaneous injection | subcutaneous or topical |
| Common vials | 5 mg, 10 mg | 50 mg, 100 mg |
| Typical mix | 5 mg + 2 ml water | 50 mg + 5 ml water |
| Units for typical dose | 10 units (250 mcg) | 10 units (1 mg) |
What each actually does
BPC-157 promotes angiogenesis and growth-factor signaling around damaged musculoskeletal and GI tissue — rodent data across tendon, muscle, nerve and gut models. GHK-Cu is a naturally occurring copper-binding tripeptide that declines with age; it upregulates collagen, elastin and decorin production and modulates inflammation — the reason it's a staple in cosmetic dermatology literature.
Route matters more than usual
BPC-157 is essentially an injection compound (oral variants exist for gut-focused use). GHK-Cu splits by goal: topical creams and microneedling serums for face and hair, subcutaneous injections (1–2 mg daily ranges in community protocols) for systemic remodeling. Injected GHK-Cu stings notoriously — a practical reason many keep it topical.
Timeline expectations
BPC-157 protocols run in rehab windows: 4–8 weeks around an injury. GHK-Cu is a slow remodeler — skin and hair changes are judged in months, and it's often cycled continuously at low dose. Neither is a quick fix; they're just slow on different clocks.
Can you stack them?
Common combo in recovery circles: BPC-157 (+ TB-500) for the structural injury, GHK-Cu topically for scar and skin quality over the same period. No known antagonism; they occupy different pathways.
More comparisons
Educational comparison based on commonly published research protocols — not medical advice or an endorsement of any compound.